Vivimed Labs Limited stock analysis
Want to see IN:VIVIMEDLAB full AI Analyst Report?
Vivimed Labs Limited (VIVIMEDLAB) Stock Price & Analysis
VIVIMEDLAB Stock Chart & Stats
- Day’s Range
- INR 5.44 - INR 5.44
- 52-Week Range
- INR 4.76 - INR 27.99
- Previous Close
- INR 5.55
- Volume
- N/A
- Average Volume (3M)
- 7,644
- Market Cap
- INR 460.17M
- Enterprise Value
- INR 4.24B
- Total Cash (Recent Filing)
- INR 13.56M
- Total Debt (Recent Filing)
- INR 3.97B
- Price to Earnings (P/E)
- ―
- Beta
- 0.19
- Next Earnings
- Feb 15, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Sep 19, 2018
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Niche Pharmaceutical And Specialty-chemical Platform
The combination of APIs, intermediates, finished formulations and contract manufacturing gives Vivimed multiple ways to participate in pharmaceutical value chains. Its niche-molecule focus and chemistry capabilities can support specialized customer relationships and provide a foundation for durable market participation.
Exposure To Regulated And Semi-regulated Markets
Operating across regulated and semi-regulated markets gives Vivimed exposure to established pharmaceutical demand and applications tied to human health. This market positioning can support longer-term relevance because products and manufacturing capabilities serve recurring industry requirements rather than purely discretionary demand.
Improved Recent Cash Generation
Positive operating and free cash flow in 2026 is a constructive improvement from negative cash flow in 2024 and 2025. If sustained, internally generated cash could help support operations and reduce reliance on external funding, although the broader cash-generation record remains volatile.
Bears Say
Persistent Revenue Contraction
Revenue shrinking consistently across the 2022–2026 period indicates deterioration in the company’s scale and market traction rather than a single temporary setback. A contracting top line reduces operating leverage, limits reinvestment capacity, and makes recovery in profitability more difficult.
Deep And Sustained Unprofitability
Recurring operating and net losses show that Vivimed has not converted its pharmaceutical and specialty-chemical activities into sustainable earnings. The sharp 2026 margin deterioration, including negative gross profit, increases concern that the cost base and pricing economics remain structurally unfavorable.
Negative Equity And High Debt
Negative equity means accumulated losses have eroded the capital base, while substantial debt leaves limited financial flexibility. This combination can constrain investment in growth, increase dependence on creditors, and make the business more vulnerable if losses or weak cash generation persist.
Vivimed Labs Limited News
VIVIMEDLAB FAQ
What was Vivimed Labs Limited’s price range in the past 12 months?
What is Vivimed Labs Limited’s market cap?
When is Vivimed Labs Limited’s upcoming earnings report date?
How were Vivimed Labs Limited’s earnings last quarter?
Is Vivimed Labs Limited overvalued?
Does Vivimed Labs Limited pay dividends?
What is Vivimed Labs Limited’s EPS estimate?
How many shares outstanding does Vivimed Labs Limited have?
What happened to Vivimed Labs Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vivimed Labs Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Vivimed Labs Limited
Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug formulations, specialized chemicals, and consumer-branded remedies. Its global presence extends across markets such as India, Mexico, Spain, and Hungary, among others. The company's operations are divided into two core segments: the Pharmaceutical Business and the Specialty Chemicals Business. Within its Pharmaceutical division, Vivimed Labs supplies APIs and crucial intermediates to both generic and ethical pharmaceutical companies. It also develops and markets proprietary branded formulations catering to therapeutic areas like ophthalmology, nutraceuticals, dermatology, and pain relief. Additionally, it provides contract manufacturing services for a variety of dosage forms, including capsules, tablets, syrups, liquids, nasal sprays, and ointments. A notable product is Favulous, manufactured for the treatment of mild to moderate COVID-19 cases. The Specialty Chemicals segment boasts a broad portfolio. This includes Jarocol-branded hair dye intermediates essential for permanent, semi-permanent, and temporary hair coloring systems, alongside oxidation dye couplers, bases, and direct and basic dyes. It also produces Reversacol-branded photochromic dyes and antimicrobial agents utilized in applications ranging from plastic additives to antibacterial handwashes. Furthermore, the company manufactures photographic chemicals, such as black and white developers and antifog additives, for medical and industrial X-ray imaging, consumer photography, and graphic arts litho-plate production. Collectively, Vivimed Labs' offerings find extensive application in the home, personal, and industrial care sectors.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Manohar Rao Varalwar
- Employees
- 586
- Website
- www.vivimedlabs.com
- Address
- 6-3-866/1/G 1, GMR Towers, Hyderabad, TS, 500016, IN
Vivimed Labs Limited (VIVIMEDLAB) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 14 |
| Technical Analysis | 6 | 1 | 2 |
| Moving Averages | 0 | 0 | 12 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:GRANULESGranules India Limited | ||
| IN:HIKALHikal Limited | ||
| IN:LAURUSLABSLaurus Labs Ltd. | ||
| IN:NEULANDLABNeuland Laboratories Ltd. | ||
| IN:SOLARASolara Active Pharma Sciences Ltd. |
